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OBJECTIVES The purpose of this study was to evaluate the efficacy of various antiarrhythmic drugs at
prolonging the QT interval into the normal range and preventing ventricular arrhythmias in
patients with short QT syndrome.
BACKGROUND Short QT syndrome is a recently described genetic disease characterized by short QT interval,
high risk of sudden death, atrial fibrillation, and short refractory periods.
METHODS Six patients with short QT syndrome, five of whom had received an implantable cardioverter-
defibrillator (ICD) and one child, were tested with different antiarrhythmic drugs, including
flecainide, sotalol, ibutilide, and hydroquinidine, to determine whether they could prolong the
QT interval into the normal range and thus prevent symptoms and arrhythmia recurrences.
RESULTS Class IC and III antiarrhythmic drugs did not produce a significant QT interval prolongation.
Only hydroquinidine administration caused a QT prolongation, which increased from 263 
12 ms to 362  25 ms (calculated QT from 290  13 ms to 405  26 ms). Ventricular
programmed stimulation showed prolongation of ventricular effective refractory period to
200 ms, and ventricular fibrillation was no longer induced.
CONCLUSIONS The ability of quinidine to prolong the QT interval has the potential to be an effective therapy
for short QT patients. This is particularly important because these patients are at risk of
sudden death from birth, and ICD implant is not feasible in very young children. (J Am
Coll Cardiol 2004;43:1494–9) © 2004 by the American College of Cardiology Foundationc
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fhort QT syndrome is a recently described genetic syn-
rome characterized by constantly short QT intervals, high
amilial incidence of palpitations, syncope, sudden death
nd atrial fibrillation, short refractory periods (ERPs), and
nducible ventricular fibrillation at electrophysiologic study
1). At the moment, little is known about the effects of
ntiarrhythmic drugs in these patients. Because of the high
ncidence of sudden cardiac death and the absence of known
harmacologic therapy, the implantation of an automatic
ardioverter-defibrillator (ICD) is the only available ther-
py. This syndrome confers a risk of sudden death to
ffected infants and, thus, it is particularly important to
xplore an alternative therapy to ICDs, as ICD implant is
ot feasible in very young children.
In the present study, various antiarrhythmic drugs were
dministered to patients with short QT syndrome to eval-
ate whether they could prolong the QT interval into the
ormal range and, thus, potentially prevent symptoms and
rrhythmia recurrences.
ETHODS
atients. Six patients with short QT syndrome from two
ifferent families were included in the present study. The
From the *Division of Cardiology, Ospedale Civile di Asti, Asti, Italy; †Depart-
ent of Medicine, University Hospital Mannheim, University of Heidelberg,
annheim, Germany; ‡Division of Cardiology, Haut-Leveque, Bordeaux-Pessac,
rance; §Department of Cardiac Diseases, San Filippo Neri Hospital, Rome, Italy;
nd the Molecular Genetics and ¶Experimental Cardiology Programs, Masonic
edical Research Laboratory, Utica, New York.
Manuscript received December 17, 2003; revised manuscript received February 11,004, accepted February 17, 2004.linical characteristics of the two families have been previ-
usly published (1). In the first family, six subjects from four
ifferent generations had a cardiac arrest; among them, one
ied suddenly at the age of three months and one was
esuscitated at the age of six months; the last one and other
wo patients with short QT were tested with different drugs.
n the second family, three people from three generations
ied suddenly, and in three living subjects with short QT,
ifferent drugs were evaluated.
All patients had experienced symptomatic palpitations
nd two had experienced syncopal events.
The five adult patients underwent electrophysiologic
tudy: four of them had inducible ventricular fibrillation and
ll received an ICD. The child had suffered serious neuro-
ogic damage owing to the prolonged cardiac arrest and did
ot undergo electrophysiologic study or ICD implantation.
T measurement. Twelve-lead electrocardiographic
ECG) recordings were obtained at baseline and on each
gent after steady-state was reached (5 half-lives). The
T interval was measured at a speed of 25 and 50 mm/s by
wo independent investigators blinded as to which drug was
iven. As most correction formulae are known to overcor-
ect at high heart rates and undercorrect at low heart rates,
he ECGs were accepted for QT evaluation if the heart rate
as between 60 and 100 beats/min. The QT interval was
orrected for heart rate using Bazett’s formula and the
ormula proposed by Rautaharju et al. (2), who analyzed
CGs from 14,379 healthy individuals and proposed a
ormula by which QT interval could be predicted: QTp (ms)
656/(1  heart rate/100). The QT interval was then
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April 21, 2004:1494–9 Short QT and Drugsompared with the QTp (QT/QTp%). Two standard de-
iations below the mean value is 88% of the QTp. The QT
nterval was considered significantly prolonged as compared
o basal values if calculated QT (QTc) exceeded 350 ms or
0% of the predicted value based on the Rautaharju et al. (2)
ormula. If QT interval prolongation to the normal range
as observed in patients with ICDs, ventricular pro-
rammed stimulation via the ICD lead was performed to
valuate ERPs and ventricular arrhythmia inducibility.
rug testing. The following agents were tested: flecainide,
otalol, ibutilide, and hydroquinidine (Table 1). The order
n which the medications were given was not randomized.
atients were hospitalized while undergoing the drug test-
ng. Flecainide, a class IC antiarrhythmic drug, was admin-
stered intravenously (IV) at a dose of 2 mg/kg in 10 min.,
nd orally, at a dose of 100 mg twice a day (b.i.d.); the child
eceived 25 mg b.i.d (3.3 mg/kg). Two class III agents were
ested: ibutilide was administered at the dosage of 1 mg
0.016 mg/kg) IV in 10 min; sotalol was administered IV at
dose of 50 mg and orally at the maximal tolerated dosage.
ydroquinidine, a class IA drug, was administered in the
ong-acting formulation at a dosage of 250 mg three times
day (t.i.d.) orally or 500 mg b.i.d; the child received 125
g b.i.d. (16 mg/kg).
ESULTS
able 1 shows QRS and QT values in basal conditions and
fter drug administration. Oral flecainide produced a slight
T increase in the four patients in which it was adminis-
ered, either IV or orally, mainly due to QRS prolongation.
butilide (two patients) and oral or IV sotalol (three pa-
ients) caused no changes of QT interval. The two patients
eceiving oral sotalol tolerated only a maximal dosage of
0 mg b.i.d. owing to bradycardia and/or hypotension.
otalol was not tolerated by the child because of asthma.
ydroquinidine was administered to six patients. The child
Patient 3) required discontinuation after the first four doses
Abbreviations and Acronyms
b.i.d.  twice a day
ECG  electrocardiographic/electrocardiography/
electrocardiogram
ERP  effective refractory period
ICa  slow inward Ca current
ICD  implantable cardioverter-defibrillator
IKr  rapid component of the delayed rectifier
potassium current
IKs  slow component of the delayed rectifier
potassium current
INa  inward sodium current
Ito  transient outward potassium current
IV  intravenously
QTc  calculated QT
QTp  predicted QT
t.i.d.  three times a dayecause of asthma and diarrhea. In the remaining five tatients, hydroquinidine caused QT prolongation, which
eached the normal range, varying from 263  12 ms to
62 25 ms (QTc from 290 13 ms to 405 26 ms) and
eaching values of QT/QTp 90%. Moreover an ST-
egment, which was almost absent at basal recording,
ppeared and the T-wave, which was tall and peaked,
ncreased in duration and decreased in amplitude (Fig. 1).
entricular programmed stimulation was repeated via the
CD lead in five patients while they were on hydroquinidine
reatment. In all patients, the ventricular ERP was pro-
onged to  200 ms (from 145  13 ms to 220  22 ms)
nd ventricular arrhythmias were not inducible in any
atient after drug administration, whereas they had been
nduced in four out of five patients at basal electrophysi-
logic study. Hydroquinidine caused severe diarrhea also in
atient 2, which required drug discontinuation after one
onth. In the two patients who had diarrhea on hydro-
uinidine, potassium was maintained in the normal range.
oth patients were then treated with oral flecainide.
The follow-up after ICD implantation was 11  3
onths. All patients remained asymptomatic for palpita-
ions and syncope, and no ventricular arrhythmias were
etected by the ICD.
ISCUSSION
n the past years, several familial syndromes with the common
haracteristic of an association between repolarization abnor-
alities at ECG, ventricular arrhythmias, and sudden death
ave been described (3–6). In recent years, molecular studies
ave clarified that, in most cases, abnormalities in the mem-
rane ion channels were involved, and genetic screening has
dentified several mutations in genes encoding for cardiac ion
hannel proteins and related them to the different phenotypes
7,8).
Recently, short QT syndrome, a new genetic disease with
utosomal dominant inheritance, has been described (1,9).
hese subjects have a short QT interval at ECG (300 ms),
ith only slight modifications with heart rate changes, often
all and peaked T waves, and structurally normal heart.
hey experience symptomatic palpitations and syncope and
ay die suddenly, even during infancy. In these patients,
oth ventricular fibrillation and atrial arrhythmias (atrial
brillation and flutter) have been documented. At electro-
hysiologic study, very short atrial and ventricular refractory
eriods and easy inducibility of ventricular fibrillation have
een observed (1).
The very short QT interval and the symmetrical T waves
f high amplitude may depend on increased phase 2 and
hase 3 outward potassium currents in all three transmural
ell types (epicardial, M cells, endocardial) (9–11). The first
ypothesis we made on short QT patients was that an
bnormality of the rapid component of the delayed rectifier
otassium current (IKr) causing a gain of function could be
esponsible for the action potential and refractoriness reduc-
ion; for this reason, patients were treated with two different
Table 1. Drugs and Electrocardiographic Modifications
Family Pt #
Age,
Gender Drug Route Dose Rhythm HR
QRS
(ms)
QT
(ms)
QTc
(ms)
QT/QTp
(%)*
1 1 35, M none # # sinus 66 80 270 283 68
1 flecainide i.v. 2 mg/kg sinus 62 90 300 305 74
1 flecainide oral 100 mg b.i.d. sinus 60 100 320 320 78
1 sotalol oral 80 mg b.i.d. sinus 63 80 260 266 65
1 ibutilide i.v. 1 mg/kg sinus 60 80 290 290 71
1 hydroquinidine s.r. oral 250 mg t.i.d. sinus 60 100 380 380 93
2 31, F none # # sinus 86 80 250 299 71
2 flecainide i.v. 2 mg/kg sinus 80 90 240 277 66
2 flecainide oral 100 mg b.i.d. sinus 83 100 240 282 67
2 sotalol oral 80 mg b.i.d. sinus 63 80 280 287 70
2 ibutilide i.v. 1 mg sinus 67 80 280 296 71
2 hydroquinidine s.r. oral 250 mg t.i.d. sinus 85 100 360 428 102
3 6, M none # # sinus 76 70 250 281 67
3 sotalol not tolerated
3 flecainide oral 25 mg b.i.d. sinus 68 90 280 298 72
3 hydroquinidine not tolerated
2 4 67, F none # # sinus 72 120 270 296 71
4 flecainide i.v. 2 mg/kg sinus 73 150 320 350 84
4 hydroquinidine s.r. oral 500 mg b.i.d. sinus 83 120 370 435 103
5 40, F none # # sinus 72 100 280 307 73
5 sotalol i.v. 50 mg sinus 81 100 260 302 72
5 hydroquinidine s.r. oral 500 mg b.i.d. sinus 66 100 380 380 96
6 15, M none # # sinus 66 85 260 273 66
6 hydroquinidine s.r. oral 500 mg b.i.d. sinus 95 100 320 403 95
*QTp  QT predicted (2). #  none.
b.i.d.  twice a day; HR  heart rate; i.v.  intravenous; s.r.  slow release; t.i.d.  3 times a day.
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April 21, 2004:1494–9 Short QT and Drugsigure 1. Twelve-lead electrocardiographic (ECG) recordings of Patient 1, while treated with different antiarrhythmic drugs. From left to right: basal
CG; during oral flecainide administration, oral sotalol, ibutilide, and hydroquinidine. During hydroquinidine administration: QT prolongation and ST-T
hanges: appearance of ST-segment, T-wave increases in duration.
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Short QT and Drugs April 21, 2004:1494–9elective IKr-blocking agents: sotalol and ibutilide. How-
ver, treatment with these drugs demonstrated a lack of
ffect on the repolarization phase. This lack of effect could
ave two possible explanations: first, IKr may not be
nvolved; second, IKr is involved but it does not physiolog-
cally respond to its selective blockers. If IKr channels were
ormal, they should respond normally to these blocking
gents, which would result in a QT prolongation also in
hort QT patients. Thus, the second hypothesis seems to be
ore attractive.
Very recently two different missense mutations have been
escribed in the short QT families in the human ether-a-
o-go gene (HERG), resulting in the same amino acid
hange in the S5-P loop region of the cardiac IKr channel.
he mutations dramatically increase IKr leading to hetero-
eneous abbreviation of action potential duration and re-
ractoriness and rendering the channel relatively unrespon-
ive to IKr blockers (12). These findings explain why
elective IKr blockers, such as class III antiarrhythmic
gents sotalol and ibutilide, did not prolong QT interval in
hese patients. The mutation must have caused the loss of
ome of the physiologic regulatory mechanisms, and the ion
hannel is no longer sensitive to a drug that normally has a
pecific action on it.
Flecainide is a Na channel-blocking agent that also has
blocking effect on IKr, inward rectifier Kt current (IK1),
nd transient outward potassium current (Ito); it is known
o increase the ERPs and reduce the conduction velocity in
tachycardia-dependent manner, and this would result in
n antifibrillatory effect, as reported in experimental studies
13,14). The effect on the action potential prolongation of
ecainide is considerably less than that of the class IA
gents. In short QT patients, acute administration of these
rugs resulted in a slight refractoriness prolongation (1), and
uring chronic treatment only a slight QT interval prolon-
ation was observed.
Quinidine produced a marked prolongation of the QT
nterval, which then entered the normal range, and of
entricular ERPs, preventing ventricular fibrillation induc-
ion. Furthermore, quinidine treatment produced ST-T
hanges, with an obvious ST-segment and broader T-wave.
uinidine exerts a use-dependent block of the fast inward
odium current (INa), with a greater depression of the rapid
pstroke of the action potential at faster rates, the slowly
nactivating tetrodoxin-sensitive Na current, and the slow
nward calcium current (ICa). Quinidine also blocks rapid
IKr) and the slow (IKs) components of the delayed rectifier
otassium current, the inward rectifier IK1, the ATP-
ensitive K channel IKATP, and Ito. The effects of the
lock of K currents explain the prolongation of the action
otential (13,14) that is involved in its antiarrhythmic effect.
greater affinity of quinidine for the open state of the IKr
hannel (14) may also make the drug more effective in
nhibiting IKr than other blockers of the current such as
-sotalol. Acting on different K currents and particularly for
ts ability to block the slow component of the delayedectifier current IKs, quinidine could act on short QT
atients producing a re-equilibration of the ionic currents in
he presence of an abnormal, hyperfunctioning one (IKr). It
hould be considered that an agent may be active in
roducing electrophysiologic effects acting on the specific
bnormal current, but also with an action on other channels
nvolved in the same or in other phases of the action
otential. The final effect would be a reduction of the
arkedly augmented repolarizing forces with prolongation
f the ventricular ERP and of the QT interval.
The finding that quinidine effectively prolongs the QT
nterval and ventricular ERP and prevents ventricular ar-
hythmias induction suggests that it may be considered as a
otential therapy for short QT patients. This is particularly
mportant because these patients are at risk of sudden death
rom birth, and ICD implant is not feasible in very young
hildren. Moreover, quinidine therapy could be proposed to
atients who refuse an ICD or to those who are getting
requent shocks from the ICD. Quinidine should be con-
idered the most effective pharmacologic therapy in these
atients; flecainide may be the second choice when quini-
ine is not tolerated, while other drugs with action on
arious potassium channels, such as azimilide, which acts on
oth IKr and IKs, are under investigation.
Finally, ICD implant is presently the first-choice therapy in
hort QT patients (15). Only long-term follow-up of patients
ith ICDs who receive quinidine will be able to clarify whether
his drug may be an alternative to ICD implantation.
eprint requests and correspondence: Dr. Fiorenzo Gaita, Di-
ision of Cardiology, Ospedale Civile di Asti, Via Botallo, 2, Asti,
taly. E-mail: gaitaf@libero.it.
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